60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AccesswireNov 22 09:00 ET

H.C. Wainwright Maintains Can-Fite BioPharma(CANF.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsNov 12 08:31 ET · Ratings

Promising Developments and Expanding Indications for Can-Fite BioPharma's Namodenoson: Analyst Recommends Buy

TipRanksNov 12 07:35 ET

Express News | HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $18 Price Target

BenzingaNov 12 06:53 ET

Can-Fite Achieves Milestone With First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

GlobeNewswireNov 11 07:00 ET

Can-Fite BioPharma Announces an Update Related to IP Status of Namodenoson

TipRanksNov 4 07:26 ET